Tina Cascone

12.9k total citations · 4 hit papers
104 papers, 3.4k citations indexed

About

Tina Cascone is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Tina Cascone has authored 104 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Oncology, 67 papers in Pulmonary and Respiratory Medicine and 24 papers in Molecular Biology. Recurrent topics in Tina Cascone's work include Lung Cancer Treatments and Mutations (50 papers), Cancer Immunotherapy and Biomarkers (44 papers) and Lung Cancer Diagnosis and Treatment (26 papers). Tina Cascone is often cited by papers focused on Lung Cancer Treatments and Mutations (50 papers), Cancer Immunotherapy and Biomarkers (44 papers) and Lung Cancer Diagnosis and Treatment (26 papers). Tina Cascone collaborates with scholars based in United States, Italy and Canada. Tina Cascone's co-authors include John V. Heymach, Monique B. Nilsson, Fortunato Ciardiello, Xiuning Le, Boris Sepesi, Sonia Patel, Rakesh K. Jain, Maria Pia Morelli, Walter Weder and Andreas Rimner and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Tina Cascone

97 papers receiving 3.3k citations

Hit Papers

Molecular Mechanisms and Future Implications of VEGF/VEGF... 2021 2026 2022 2024 2022 2021 2024 2023 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
    2022 254 citations Sonia Patel, Monique B. Nilsson et al. Clinical Cancer Research profile →
  2. Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
    2021 222 citations Jamie E. Chaft, Tina Cascone et al. Nature Reviews Clinical Oncology profile →
  3. Neoadjuvant Chemoimmunotherapy for NSCLC
    2024 89 citations Boris Sepesi, Patrick M. Forde et al. profile →
  4. LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC
    2023 67 citations Tina Cascone, Mark M. Awad et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tina Cascone United States 30 1.8k 1.6k 1.4k 684 331 104 3.4k
Ernest Nadal Spain 34 1.8k 1.0× 1.8k 1.2× 1.5k 1.1× 815 1.2× 361 1.1× 169 3.6k
Ferdinandos Skoulidis United States 22 1.8k 1.0× 1.4k 0.9× 1.4k 1.0× 729 1.1× 376 1.1× 73 3.1k
Ximing Tang United States 32 1.7k 0.9× 1.6k 1.0× 1.9k 1.4× 1.0k 1.5× 211 0.6× 70 3.8k
Vincenzo Damiano Italy 26 1.9k 1.0× 1.2k 0.7× 1.4k 1.0× 459 0.7× 201 0.6× 62 3.2k
Hatim Husain United States 25 1.4k 0.8× 1.4k 0.9× 1.0k 0.7× 1.2k 1.7× 167 0.5× 72 2.7k
Vienna Ludovini Italy 33 2.1k 1.2× 2.0k 1.2× 1.3k 1.0× 900 1.3× 205 0.6× 102 3.5k
Kazunori Tsukuda Japan 34 1.5k 0.8× 1.5k 0.9× 2.1k 1.5× 1.0k 1.5× 155 0.5× 121 3.7k
Santiago Viteri Spain 31 2.1k 1.2× 2.1k 1.4× 1.3k 1.0× 903 1.3× 341 1.0× 169 3.4k
Sandra O’Toole Australia 35 1.9k 1.0× 1.0k 0.6× 2.5k 1.8× 1.4k 2.0× 375 1.1× 105 4.3k
In‐Gu Do South Korea 31 1.0k 0.6× 691 0.4× 1.1k 0.8× 516 0.8× 340 1.0× 97 2.5k

Countries citing papers authored by Tina Cascone

Since Specialization
Citations

This map shows the geographic impact of Tina Cascone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tina Cascone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tina Cascone more than expected).

Fields of papers citing papers by Tina Cascone

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tina Cascone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tina Cascone. The network helps show where Tina Cascone may publish in the future.

Co-authorship network of co-authors of Tina Cascone

This figure shows the co-authorship network connecting the top 25 collaborators of Tina Cascone. A scholar is included among the top collaborators of Tina Cascone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tina Cascone. Tina Cascone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rahal, Zahraa, et al.. (2025). Tumour and microenvironment crosstalk in NSCLC progression and response to therapy. Nature Reviews Clinical Oncology. 22(7). 463–482. 7 indexed citations
2.
Vaccaro, Alessandra, Zahraa Rahal, Humam Kadara, & Tina Cascone. (2025). A Roadmap to Precision Immunotherapy for Early-Stage Non–Small Cell Lung Cancer. Cancer Discovery. 15(5). 884–889. 4 indexed citations
3.
Provencio, Mariano, Mark M. Awad, Tina Cascone, et al.. (2024). LBA50 Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study. Annals of Oncology. 35. S1239–S1240. 9 indexed citations
4.
Awad, Mark M., Tina Cascone, Jonathan Spicer, et al.. (2024). LBA2 Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study. ESMO Open. 9. 102985–102985. 2 indexed citations
5.
Khushalani, Nikhil I., Patrick A. Ott, Robert L. Ferris, et al.. (2024). Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 12(3). e007364–e007364. 18 indexed citations
6.
7.
8.
Forde, Patrick M., Solange Peters, S. Meadows–Shropshire, et al.. (2024). PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816. Journal of Thoracic Oncology. 19(10). S2–S2. 14 indexed citations
9.
Cascone, Tina, Laura Bonanno, M. A. Lieberman, et al.. (2024). PL02.07 Neocoast-2: Efficacy and Safety of Neoadjuvant Durvalumab (D) + Novel Anticancer Agents + CT and Adjuvant D ± Novel Agents in Resectable NSCLC. Journal of Thoracic Oncology. 19(10). S1–S2. 6 indexed citations
10.
Xu, Ting, Ajay Sheshadri, Anita Deswal, et al.. (2023). Comorbidities and Their Impact on Treatment Tolerance and Outcome in Elderly NSCLC Patients Treated with Concurrent Chemoradiation Using Proton or Photon Followed by Immunotherapy. International Journal of Radiation Oncology*Biology*Physics. 117(2). e54–e55. 1 indexed citations
11.
Cascone, Tina, Mark M. Awad, Jie He, et al.. (2023). LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. Annals of Oncology. 34. S1295–S1295. 67 indexed citations breakdown →
12.
Tran, Hai T., Simon Heeke, Sheeba J. Sujit, et al.. (2023). Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer. Annals of Oncology. 35(2). 183–189. 32 indexed citations
13.
Patel, Sonia, Monique B. Nilsson, Yan Yang, et al.. (2023). IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC. Clinical Cancer Research. 29(7). 1292–1304. 62 indexed citations
14.
Burton, Elizabeth M., Rodabe N. Amaria, Tina Cascone, et al.. (2022). Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021. Journal of Translational Medicine. 20(1). 271–271. 6 indexed citations
15.
Patel, Sonia, Monique B. Nilsson, Xiuning Le, et al.. (2022). Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy. Clinical Cancer Research. 29(1). 30–39. 254 indexed citations breakdown →
16.
Sepesi, Boris, Tina Cascone, Stephen G. Chun, Mehmet Altan, & Xiuning Le. (2020). Emerging Therapies in Thoracic Malignancies—Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non–Small Cell Lung Cancer. Surgical Oncology Clinics of North America. 29(4). 555–569. 8 indexed citations
17.
Cascone, Tina, Kathryn A. Gold, Stephen G. Swisher, et al.. (2017). Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery. 105(2). 418–424. 20 indexed citations
18.
Mehran, Reza J., Monique B. Nilsson, Mehrdad Khajavi, et al.. (2014). Tumor Endothelial Markers Define Novel Subsets of Cancer-Specific Circulating Endothelial Cells Associated with Antitumor Efficacy. Cancer Research. 74(10). 2731–2741. 40 indexed citations
19.
Wagner, Klaus W., Hunain Alam, Shilpa S. Dhar, et al.. (2013). KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. Journal of Clinical Investigation. 123(12). 5231–5246. 149 indexed citations
20.
Iovino, Francesco, Francesca Ferraraccio, Michele Orditura, et al.. (2008). Serum Vascular Endothelial Growth Factor (VEGF) Levels Correlate with Tumor VEGF and p53 Overexpression in Endocrine Positive Primary Breast Cancer. Cancer Investigation. 26(3). 250–255. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ernest Nadal Breakdown of academic impact, for papers by Ferdinandos Skoulidis Breakdown of academic impact, for papers by Ximing Tang Breakdown of academic impact, for papers by Vincenzo Damiano Breakdown of academic impact, for papers by Hatim Husain Breakdown of academic impact, for papers by Vienna Ludovini Breakdown of academic impact, for papers by Kazunori Tsukuda Breakdown of academic impact, for papers by Santiago Viteri Breakdown of academic impact, for papers by Sandra O’Toole Breakdown of academic impact, for papers by In‐Gu Do
Rankless by CCL
2026